Assessing the yield and safety of endoscopy in acute graft-vs-host disease after hematopoietic stem cell transplant

Table 1 Baseline demographics and clinical characteristics

Demographics and clinical characteristics	n = 195
Age (yr), median (range)	56 (17-78)
Female, n (%)	101 (51.8)
Time since HSCT in days, median (range)	27 (9-98)
Hematologic disorder, n (%)1
AML	80 (41.0)
B-ALL	34 (17.4)
MDS	30 (15.4)
Myelofibrosis	13 (6.7)
Presenting symptoms, n (%)1
Diarrhea	144 (73.9)
Nausea/vomiting	107 (54.9)
Abdominal pain	50 (25.6)
Gross endoscopic findings, n (%)1
Edema/erythema	108 (55.4)
Gastritis	84 (43.1)
Ulcerations/erosions	56 (28.7)
Colitis	39 (20.0)
Esophagitis	27 (13.9)
Duodenitis	26 (13.3)
Normal	25 (12.8)
Pathologic findings, n (%)1
Mild GVHD	133 (68.2)
Chronic inflammation	41 (21.0)
Moderate GVHD	36 (18.5)
Ulceration/erosion	25 (12.8)
Severe GVHD	16 (8.2)
Location of pathologic findings, n (%)1
Sigmoid colon	118 (60.5)
Stomach	105 (53.9)
Rectum	103 (52.8)
Duodenum	94 (48.2)
Pre-procedure lab values, median (range)
Hemoglobin (g/dL)	9.0 (6.7-14.4)
Platelets (× 103/µL)	80 (16-388)
ANC (× 103/µL)	2.6 (0.0-23.0)
INR	1.0 (0.9-1.7)
BUN	14 (2-78)
Creatinine	0.70 (0.28-3.32)
Pre-procedure transfusions, n (%)
1 or more units of platelets transfused	78 (40.0)
1 or more units of pRBCs transfused	55 (28.2)
1 or more units of FFP transfused	3 (1.5)
Immunosuppressant use within 1-wk pre-procedure, n (%)1
Tacrolimus	164 (84.1)
Sirolimus	115 (59.0)
Mycophenolate	70 (35.9)
Methylprednisone	55 (28.2)
Hydrocortisone	49 (25.1)

¹Only the most common findings were included in this table. FFP: Fresh frozen plasma/cryoprecipitate; pRBCs: Packed red blood cells; BUN: Blood urea nitrogen; INR: International normalized ratio; ANC: Absolute neutrophil count; AML: Acute myelogenous leukemia; B-ALL: B-cell acute lymphoblastic leukemia; MDS: Myelodysplastic syndromes; GVHD: Graft-vs-host disease; HSCT: Hematopoietic stem cell transplant.